Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710458 | 0.88 | KMT2A (0.60) | KMT2AL3MBTL1 | |
| SCHEMBL3351581 | 0.79 | SIGMAR1 (0.60) | — | |
| SCHEMBL31291922 | 0.78 | SCN9A (0.45) | KMT2AL3MBTL1SCN9A | |
| SCHEMBL31291853 | 0.78 | SCN9A (0.45) | KMT2AL3MBTL1SCN9A | |
| SCHEMBL4231721 | 0.77 | DRD2 (0.55) | KMT2AL3MBTL1KDM4D | |
| SCHEMBL2030049 | 0.77 | DRD2 (0.55) | KMT2AL3MBTL1KDM4D | |
| SCHEMBL4855029 | 0.75 | KMT2A (0.71) | KMT2AL3MBTL1 | |
| SCHEMBL5847914 | 0.75 | BTK (0.43) | KMT2AL3MBTL1 | |
| SCHEMBL18763112 | 0.73 | KMT2A (0.43) | KMT2AL3MBTL1KDM4DSCN9A | |
| SCHEMBL18763097 | 0.73 | KMT2A (0.43) | KMT2AL3MBTL1KDM4DSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | CHEK1, PCNA, CHEK2 | KMT2A 1546/4885L3MBTL1 310/4885KDM4D 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.